10x Genomics (TXG) reported a Q4 loss Thursday of $0.13 per diluted share, narrowing from a loss of $0.40 a year earlier.
Analysts polled by FactSet expected a loss of $0.20.
Revenue for the three months ended Dec. 31 was $166 million, up from $165 million a year earlier.
Analysts surveyed by FactSet expected $159.7 million.
For the full year 2026, the company expects revenue of $600 million to $625 million. Analysts expect $611.6 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.